Brand Name
Alyftrek
Generic Name
Tezacaftor
View Brand Information FDA approval date: December 20, 2024
Classification: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Form: Tablet
What is Alyftrek (Tezacaftor)?
ALYFTREK is indicated for the treatment of cystic fibrosis in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene [see Clinical Pharmacology (1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Summary: Cystic Fibrosis (CF) is a genetic disease that affects multiple organs and systems. In recent years, the marketing of CFTR protein modulator drugs, such as the Elexacaftor-Tezacaftor-Ivacaftor (ETI) combination, has significantly improved patients' quality of life and prognosis. ETI, currently prescribed in Italy for CF patients over six years of age with at least one F508del mutation, has shown i...
A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
Summary: The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Sinus Disease in Young Children With Cystic Fibrosis
Summary: This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT)...
Related Latest Advances
Brand Information
ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor)
WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE
Elevated transaminases have been observed in patients treated with ALYFTREK. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients who were taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as ALYFTREK. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of elexacaftor/tezacaftor/ivacaftor
Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK, every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or elevated liver function tests at baseline
Interrupt ALYFTREK for significant elevations in liver function tests or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve, resume treatment only if the benefit is expected to outweigh the risk. Closer monitoring is advised after resuming ALYFTREK
ALYFTREK should not be used in patients with severe hepatic impairment (Child-Pugh Class C). ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and the benefit outweighs the risk. If used, monitor patients closely
1INDICATIONS AND USAGE
ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one
If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.
2CONTRAINDICATIONS
None.
3ADVERSE REACTIONS
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
- Drug-Induced Liver Injury and Liver Failure
- Hypersensitivity Reactions, Including Anaphylaxis
- Patients Who Discontinued or Interrupted Elexacaftor-, Tezacaftor-, or Ivacaftor-Containing Drugs Due to Adverse Reactions
- Intracranial Hypertension
- Cataracts
3.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The adverse reactions data below are from clinical trials of ALYFTREK in patients 6 years of age and older with CF with at least one responsive
4OVERDOSAGE
Treatment of overdosage consists of general supportive measures including monitoring of vital signs and observation of the clinical status.
5DESCRIPTION
ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor tablets) are fixed-dose combination tablets for oral use available as:
- 10 mg of vanzacaftor (equivalent to 10.6 mg of vanzacaftor calcium dihydrate), 50 mg of tezacaftor, 125 mg of deutivacaftor or
- 4 mg of vanzacaftor (equivalent to 4.24 mg of vanzacaftor calcium dihydrate), 20 mg of tezacaftor, 50 mg of deutivacaftor.
The tablets contain the following inactive ingredients: croscarmellose sodium, hypromellose, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet film coating contains Brilliant Blue FCF aluminum lake/FD&C Blue #1, carmine, hydroxypropyl cellulose, hypromellose, iron oxide red, talc, and titanium dioxide.
The active ingredients of ALYFTREK are described below.
6CLINICAL STUDIES
The efficacy of ALYFTREK in patients aged 12 years and older with cystic fibrosis (CF) who have at least one
- Trial 1 enrolled patients with CF heterozygous for
- Trial 2 enrolled patients with CF who had one of the following genotypes: homozygous for the
7HOW SUPPLIED/STORAGE AND HANDLING
ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor) tablets are supplied as follows:
8PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
9PRINCIPAL DISPLAY PANEL - 4 mg/20 mg/50 mg Tablet Wallet Carton
Rx Only
84 tablets
alyftrek™
4 mg/20 mg/50 mg
ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient.
Lift to open
10PRINCIPAL DISPLAY PANEL - 10 mg/50 mg/125 mg Tablet Wallet Carton
Rx Only
56 tablets
alyftrek™
10 mg/50 mg/125 mg
ATTENTION PHARMACIST: Dispense enclosed Medication Guide to each patient.
Lift to open
